Pediatric rheumatology

Clinical utility of CBC-Derived inflammatory markers for predicting intravenous immunoglobulin (IVIG) resistance: findings from a Korean infant Kawasaki disease cohort

Pediatr Rheumatol Online JPublished Retrospective cohort study

Authors' conclusion

MLR demonstrated moderate discriminative ability for predicting IVIG resistance in infant KD, suggesting its potential as a simple, cost-effective tool for early risk stratification in this vulnerable population.

Study context

Population
Infants under 12 months with Kawasaki disease, diagnosed January 2014–December 2024 (Korean cohort)67 IVIG-resistant (25.7%)
Participants
261 participants
Exposure
CBC-derived inflammatory markers for predicting IVIG resistance
Outcome
IVIG resistance
Methodological detailsROC curve analysis, multivariate logistic regression
  • ROC curve analysis
  • Multivariate logistic regression

Main finding

As reported in the abstract

Predictive accuracy for IVIG resistance (AUC)
GroupAUC95% CI
Monocyte-to-lymphocyte ratio (MLR)0.7760.706-0.845
Neutrophil-to-lymphocyte ratio (NLR)0.7380.670-0.806
PIV0.7340.658-0.811

AUC

Monocyte-to-lymphocyte ratio (MLR)0.776
Neutrophil-to-lymphocyte ratio (NLR)0.738
PIV0.734

95% CI

Monocyte-to-lymphocyte ratio (MLR)0.706-0.845
Neutrophil-to-lymphocyte ratio (NLR)0.670-0.806
PIV0.658-0.811

Observational data: associations, not effects.

Further findings

Independent predictors of IVIG resistance (multivariate analysis)

OR (95% CI)
MLR > 0.213.45 (1.66–7.14)
PIV > 726.682.30 (1.14–4.67)
Elevated total bilirubin1.96 (1.02–3.79)
OutcomeProportionP value
Coronary artery aneurysms, IVIG-resistant vs not16.4% vs. 5.2%P = 0.007

Original publication

Clinical utility of CBC-Derived inflammatory markers for predicting IVIG resistance: findings from a Korean infant Kawasaki disease cohort. Pediatr Rheumatol Online J. Published 18 November 2025. doi:10.1186/s12969-025-01162-8

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.